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Chapter for Lupus Book Systemic lupus erythematosus is a well-recognized 
multi-system disease. Hallmarks of the disorder include the prevalence of anti-
nuclear antibodies (ANA) and double stranded antibodies (DNA). The disease 
often presents with lupus rashes and/or arthritis or arthralgias. Lupus is “the great 
imitator,” as no organ system is excluded, when diagnosing and treating a lupus 
patient. While lupus remains evasive in novel therapies with true benefit; one issue 
has been consistent, in that the preponderance of the evidence thus far, leads to B 
cell dysfunction. More recently Belimumab was indicated for use in lupus patients. 
This is a BLyS-Specific inhibitor (B lymphocyte stimulator) medication. At this 
time, I would like to focus on lupus in a manner that you are not used to hearing. 
Typically, any practitioner who approaches a patient with a plethora of symptoms, 
would order blood tests, and conclude a diagnosis of lupus. In this chapter, I will 
point out and focus on the need to think “outside the box” and perhaps consider 
lupus as simply one of various other scenarios.
Keywords: lupus, Sjogren’s, Raynaud’s, ANA, DNA, DRV VT
1. Hallmarks of systemic lupus erythematosus
Systemic lupus erythematosus is a well-recognized multi-system disease [1].
Hallmarks of the disorder include the prevalence of antinuclear antibodies 
(ANA) and double stranded antibodies (DNA). The disease often presents with 
rashes and/or arthritis or arthralgias. Lupus is “the great imitator,” as no organ 
system is excluded, when diagnosing and treating a lupus patient.
1.1 Most recent development for lupus treatment
While lupus remains evasive in novel therapies with true benefit; one issue has 
been consistent, in that the preponderance of the evidence thus far, leads to B cell 
dysfunction. More recently Belimumab was indicated for use in lupus patients, 
which is an immunomodulator B-Lymphocyte Stimulator (BLyS)-Specific Inhibitor. 
This drug was approved by the Food and Drug Administration (FDA) for use in 
lupus patients in 2011 [2]. The majority of patients afflicted with lupus, autoreactive 
B-cells remain in the body longer than necessary. Belimumab binds to BLyS, causing 
it to no longer bind to and stimulate the autoreactive B cell.
Information recently discussed at the ACR2020, provides evidence of 
Belimumab standard therapy ameliorating the outcome for patients with active 
renal lupus. A combination of Belimumab, with either mycophenolate mofetil or 
Azathioprine, was shown to be more effective than either of these therapies alone. 
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While studies are not yet conclusive, a combination of Belimumab with cyclophos-
phamide, posed no higher risk than cyclophosphamide alone. This combination in a 
class IV nephritis group exceeded those who received cyclophosphamide alone [3].
Anifrolumab, an interleukin-1 inhibitor, was not shown to be effective in sys-
temic lupus, it did show promise in TULIP-1 and 2 and skin lesions related to lupus. 
Anifrolumab’s effect on non-skin lupus disease activity however, was nominal [4].
2. A rheum with a different view
In this section, lupus will be discussed pragmatically. Most practitioners are 
unaccustomed to viewing disease features from a rheumatologic standpoint. 
Typically, the practitioner that approaches a patient with a plethora of symptoms, 
would order blood tests, and conclude a diagnosis of lupus; however, in this part of 
the chapter, we will discuss the need to focus “outside the box” and perhaps con-
sider lupus as simply one of various other scenarios.
2.1 Finding evidence of lupus
Features of lupus considered in the differential diagnoses of other conditions 
include rashes, arthritis, renal disease (glomerular or tubular), Raynaud’s phenom-
enon, sicca syndrome and muscle weakness. The differential diagnoses for these 
features often include lymphoma, sarcoidosis, phospholipid antibody syndrome, 
rheumatoid arthritis, inflammatory myopathy, Sjogren’s syndrome, IgG4-related 
disease and scleroderma.
A lupus rash, seen with or without vasculitis, typically small vessel-showing leu-
kocytoclastic vasculitis, is seen at the dermal/epidermal junction with immunofluo-
rescence positive for IgG and complements [5]. Small vessel vasculitis is responsible 
for much of the severe abdominal pain seen in lupus patients.
Arthritis of lupus is inflammatory but not erosive. Differential diagnoses would 
include rheumatoid arthritis, gout, or psoriatic arthritis. Rheumatoid arthritis, psori-
atic arthritis, scleroderma, sarcoid and gout are all destructive arthritic diseases [6].
Renal pathology is often noted due to blood or protein in the urine. It may be 
diagnosed by a decrease in renal function, which is differentiated on biopsy. Lupus 
tends to involve glomerulus with a “full house” pattern on immunofluorescent 
staining (i.e., presence of glomerular deposits that stain for IgG, IgM, IgA, C3 
and C1q). This is the only organ finding to satisfy the SLICC criteria on its own in 
patients with systemic lupus. IgG and complements would be suggestive of lupus 
nephritis in a patient with proliferative glomerulonephritis. This may be focal, 
diffuse or pure membranous nephropathy [7]. A patient with pure membranous 
disease, high double stranded DNA and low complements often do not apply. 
Proliferative lesions are often seen in the face of rising double stranded DNA 
and consumption of complement levels. These levels are not subject to change in 
Sjogren’s, scleroderma, sarcoid, or IgG4-related disease. (IgG4-related disease is 
unique, as both tubulointerstitial diseases occur simultaneously with glomerular 
disease). ANCA vasculitis shows pauci-immune deposits [8], while sarcoid-
osis would show granulomas without positive stain for immunofluorescence. 
Goodpasture syndrome will show anti-GBM antibodies [9]. Sjogren’s syndrome 
will show renal tubular acidosis, and only rarely, glomerular disease [10]. Most 
cases of tubulointerstitial nephritis are drug-induced, and may be caused by 
medications, such as antibiotics medications, NSAIDs, proton pump inhibitors, 




combination of interstitial nephritis and nephrotic syndrome. Infections (i.e., legi-
onella or Mycobacterium tuberculosis infection), may lead to a diagnosis of tubu-
lointerstitial nephritis; however, autoimmune diseases, such as systemic lupus, 
sarcoidosis, Sjogren’s syndrome, and uveitis syndrome, are also proven to cause 
tubulointerstitial nephritis [12]. Approximately 10–20% of patients diagnosed 
with lupus nephritis, have isolated lupus membranous nephropathy (class V), with 
no associated proliferative lesion present [13]. In patients with lupus nephritis, 
tubulointerstitial interstitial nephritis may accompany glomerular lesions, which 
is a risk factor for a poor outlook [14]. The IgG4 is a diagnostic differential and 
reveals tubulointerstitial nephritis, repeatedly associated with hypocomplement-
emia and hypodense nodular lesions, which can be seen on contrast-enhanced 
computerized tomography [15]. Tissue eosinophilia and deposits in the tubular 
basement membrane are often present, in addition to the distinctive pathological 
features of the disease [16].
Pulmonary renal syndromes can be seen in a very similar fashion, adding that 
lupus may present with acute glomerulonephritis, proliferative in nature, in addi-
tion to concurrent alveolar hemorrhage or diffuse interstitial infiltrates [17]. This 
pattern of disease seen in ANCA vasculitis is predominantly granulomatous poly-
angiitis, microscopic polyangiitis, and cryoglobulinemia, which is associated with 
hepatitis C infection [18].
Oral and ocular dryness, with or without uveitis, are features of lupus [19]. 
Uveitis is frequently seen in sarcoidosis and described in IgG4-related disease and 
HLA-B27-related conditions, while corneal-related disease has a differential diagno-
sis in rheumatoid arthritis, myopathy, and phospholipid antibody syndrome.
Primary muscle weakness while in lupus, [20] is part of a differential diagnoses 
that includes polymyositis, dermatomyositis, immune mediated necrotizing myopa-
thy, lupus with myopathy, sarcoidosis with myopathy and Crohn’s with myopathy. 
The latter two, show non-caseating granuloma disease on biopsy, while lupus shows 
diffuse immunofluorescence, mainly immunoglobulins and complements. This 
could be referred to as a “recurring theme” in lupus deposits of immunoglobulin 
and complements. Cocaine-laced with levamisole is in the differential diagnosis 
systemic lupus, myopathy and vasculitis [21].
A rheumatologist should recognize a lupus patient by the malar rash sparing 
the nasolabial folds, “classic kidney biopsy” and other constellations, such as 
“non-scarring alopecia” and “discoid lupus”. These cases are often straightfor-
ward, and do not require biopsy. The classic malar rash sparing the nasolabial 
folds, is a known hallmark of lupus; although it may be confused with rosacea or 
polymorphous light eruption. The malar rash with autoantibodies, particularly 
ANA (almost 100% sensitive), and anti-double stranded DNA (95% specific), 
will lend themselves to a conclusive diagnosis [22]. Nonetheless, it should be 
noted that research criteria is not necessary for a diagnosis of lupus. The research 
criterion is merely a tool, used to randomize patients into homogeneous groups, 
while in fact physicians are treating a heterogeneous disease. So, in the quest to 
stratify patients by nonskilled physicians, or those not comfortable diagnosing or 
treating lupus properly, diagnostic criteria is often helpful, but certainly cannot 
be the quintessential element of a lupus diagnosis. In reality, actually “labeling” 
a patient with a lupus diagnosis may require a protracted course. Theoretically, 
a patient may carry a label of unspecified connective tissue disease (UCTD) for 
some time, before a conclusive diagnosis can be given. In time, this patient may 
develop lupus, Sjogren’s syndrome, rheumatoid arthritis, scleroderma, myositis, 
an overlap syndrome, anti-synthetase syndrome, Sjogren’s syndrome, IgG4-
related disease, or sarcoid.
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Positive antinuclear antibody (ANA) 97%
Malaise and fatigue 90%
Arthralgia, myalgia 90%
Sun sensitivity, skin changes 70%
Cognitive dysfunction 70%
Low C3 or C4 complement 61%
Fever due to lupus 57%









Central nervous system 32%
Increased gamma globulin 32%




Oral ulcerations (mouth, nose) 20%
Discoid lesions 20%
Central nervous system vasculitis 15%
Adenopathy 15%
Pleural effusion 12%




Approximate prevalence (%) of selected symptoms, signs, and laboratory abnormalities of systemic lupus 
erythematosus during the course of the disease in the United States [29].
2.2 Consider evidence of lupus in every disease
Physicians should consider lupus as every disease they see, and work backward 
from that point. Note the following:
1. When a patient presents with hair loss (i.e., a bald spot - non-scarring alopecia); 
the differential diagnoses are broad and lupus should be investigated, the patient 
will need to be followed and skin biopsies performed [23].
2. Lesions, such as discoid lupus, which are characteristic scaly lesions, discol-




in lupus [24]. Although these lesions may be seen in other conditions, lupus 
should be considered.
3. Uveitis, typically anterior, is common in lupus [25]. It may occur one time, and 
may be infectious. Diagnostic possibilities included syphilis, tuberculosis or 
Lyme disease. If these infections are excluded, then undoubtedly, even if the 
patient’s uveitis is a first-time occurrence, a lupus workup should be initiated.
As with all patients presenting any of the above features, clinicians should initi-
ate confirmatory laboratory workup, including phospholipids, ANA, DNA, ENA, 
SSA, and SSB, in order to establish a baseline, when a patient exhibits a potential 
lupus feature at any point. Hypothetically a young patient, between 15 and 20 years 
of age, may present to a clinic with anterior uveitis. Rather than labeling this as 
viral, the practitioner should immediately consider a differential diagnosis that 
includes lupus. Other differential possibilities would include syphilis, tuberculosis, 
HLA-B27 diseases (including but not limited to psoriatic arthritis), HLA-B27 uve-
itis, ankylosing spondylitis, reactive arthritis, Crohn’s colitis and ulcerative colitis. 
Regardless of the ultimate diagnosis, the treatment does not change; however, if the 
patient requires treatment with hydroxychloroquine, early diagnosis may lead to a 
more favorable outcome. Hydroxychloroquine is paramount. Many clinical trials 
over decades support its efficacy in prevention of lupus flares, thrombosis in lupus 
patients, and lipid-lowering potential [26].
In addition to the three presentations listed above, mouth sores also occur in 
lupus, Crohn’s disease, Behcet’s disease, phospholipid antibody syndrome, tuber-
culosis, syphilis, sarcoidosis, Sjogren’s syndrome, IgG4-related disease, and viral 
infections [27]. Viral ulcers tend to be painful. Behcet’s ulcers generally reveal 
large, circumscribed, beefy-red borders. Ulcers associated with Crohn’s disease are 
usually shallow painful ulcers, similar to those seen in sarcoidosis. Lupus ulcers are 
frequently painless and often noticed surreptitiously [28].
Additionally, isolated lymphadenopathy does not necessarily have to be hilar 
or mediastinal; it could be epitrochlear, glandular swelling, lacrimal, parotid, or 
submandibular. However, the finding, incidental or not, with or without dry eyes 
and dry mouth, may be an indication of lupus (Table 1).
3. Common presentations of lupus
The following represents selected symptoms and abnormalities in patients 
diagnosed with lupus within in the United States.
3.1 Arthropathies
Approximately 50% of lupus patients suffer from arthritis [29]. Joint disease, 
quite often a small joint polyarthritis, typically symmetric, is noted with typical 
involvement of PIPs, MCPs and wrists, inflammatory in nature; however, this is not 
erosive, which differentiates it from rheumatoid arthritis [30]. However, the prac-
titioner should keep in mind that the differential diagnosis of IgG4-related disease, 
lymphomas, Sjogren’s, sarcoidosis, or spondyloarthropathies, can also present with 
a phenotypic appearance of lupus arthritis. The definitive finding of arthritis only 
seen in lupus would be lupus arthropathy or acute rheumatic fever, which is followed 
by Jaccoud’s arthropathy. Jaccoud’s arthropathy is a chronic, non-erosive, reversible 
(with proper splinting) joint disorder that may occur after repeated bouts of arthri-
tis. This arthropathy is caused by inflammation of the joint capsule and subsequent 
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fibrotic retraction, causing ulnar deviation of the fingers, through metacarpopha-
langeal joint subluxation, primarily of the fourth and fifth fingers [31].
The greatest emphasis should be placed on the fact that all joints could be 
involved in lupus. Arthritis of lupus may be the presenting feature, and therefore, 
all cases of inflammatory arthritis must be evaluated with x-rays and a thorough 
history and physical, to exclude other diseases. Treatment would begin with the use 
of hydroxychloroquine and the addition of methotrexate. If necessary, abatacept (a 
CTLA4 inhibitor drug), could be added, as well as the newer medication discussed 
earlier, belimumab. Additionally, low dose steroids are often effective. While some 
practitioners may view steroids as poison, others feel the patient’s quality of life, on 
Prednisone (5 mg or less), even permanently could be appropriate, if this is neces-
sary for disease control and improvement in the patient’s quality of life. The patient 
should be informed of necessity for vigilance with regard to sleep, lipid and blood 
pressure monitoring, and the risk of osteoporosis. In the final analysis, the ratio of 
logic needs to be brought into consideration. As a practicing rheumatologist, with 
a personal experience of 32 years, experience dictates that 5 mg of Prednisone or 
less in virtually all the inflammatory patients that cannot be weaned, failed to cause 
significant steroid side effects. In the minority of patients who do suffer steroid 
side effects from a 5 mg daily equivalent or less as they begin to age, skin fragility 
or perhaps early cataracts can be seen; however, this may be difficult to ascertain, 
unless their ophthalmologist is convinced that any posterior subscapular cataract 
is the definite consequence of steroid use. Otherwise, this would be difficult to 
ascertain [32].
3.2 Thrombocytopenia/thrombocytosis
Approximately 42–46% of patients develop a cytopenia, including leukopenia 
and anemia [29]. Cytopenias in lupus are typically recognized with anemia, often 
hemolytic or of chronic disease, thrombocytopenia, or thrombocytosis [33]. 
Thrombocytosis indicates inflammation, while thrombocytopenia is often autoim-
mune and antiplatelet antibodies lower platelet counts; however, this should not be 
taken for granted. As in Sjogren’s, the mechanism would be hypersplenism; how-
ever, the finding of thrombocytopenia must prompt a probe for lupus. This protocol 
also stands in the case of a low white blood cell count. A WBC less than 4000 units 
for all, or lymphocyte of less than 1000, should both prompt an evaluation and 
workup for lupus. These findings while not specific are quite typical. Please note 
that one isolated sample needs repeating.
3.3 Lupus nephritis
Approximately 40% of lupus patients are diagnosed with nephritis [29]. The 
patient presents with blood or protein in the urine [34]. A renal biopsy is performed. 
A diagnosis is established - Mesangial proliferative, diffuse or focal proliferation, or 
pure membranous. The treatments for this vary. The current main stay treatment is 
mycophenolate mofetil. A new medication, which will be available in the near future, 
is calcineurin inhibitor, Voclasporin [35]. The data regarding this is promising. 
Rituximab, anecdotally, and in Pureview Data, indicates that it may also be helpful, 
although it is not the standard of care. Emphasis should be placed on the actuality 
that “the standard of care” should supersede the Food and Drug Administration’s 
indications for any drug. Approval for a drug by the Food and Drug Administration 
is solely based on the drug company’s actual “indication application” for that particu-
lar drug. While it may be used exclusively for its indication, in some cases it should 




seems to be a matter of “dollars and cents” where the pharmaceutical companies are 
concerned when determining the indication, they seek from the FDA.
3.4 Central nervous system
Roughly 32% of lupus patients develop lupus that attacks the central nervous 
system [29]. Lupus involving the central nervous system is both a confusing and 
interesting aspect of the disease [36, 37]. Virtually any central nervous system 
or peripheral nervous system problem including, but not limited to, neuropathy, 
mononeuritis multiplex, seizures, blindness, loss of hearing, cranial nerve palsy, 
encephalopathy, psychosis and movement disorders, are not uncommon in the 
lupus population, and may frequently present as an initial feature of the disease.
To reemphasize, all symptomatology that has been mentioned in this chapter 
may be an initial feature of lupus; however, the lack of swift rheumatology involve-
ment often ultimately leads to a delay in diagnosis, which is always detrimental 
to the patient. Therefore, it is important to perform a comprehensive evaluation, 
including biopsy, angiogram, or other internal organ imaging, as well as complete 
serologic testing. Additionally, most patients are not willing to take medication for 
extended periods of time, unless it can be proven to them by their physician that the 
medication will indeed benefit them by alleviating the symptoms they are experi-
encing. This will assist in a more accurate diagnosis of lupus versus another disease 
process. As in every case involving a possible autoimmune process, emphasis should 
be placed on the importance of swift initiation of workup, as this will facilitate the 
timely establishment of proper treatment.
If a patient is acutely ill with psychosis, they will typically be treated in a hos-
pital setting, being initially seen by neurology and psychiatry, as other specialists. 
Unfortunately, this occurs before a rheumatologist is consulted [38]. An immediate 
MRI of the brain and lumbar puncture should be ordered, along with autoantibod-
ies and cerebrospinal fluid, to assess the ribosomal P antibody, GAD65 antibody and 
NMO. With these proper evaluations, the likelihood of a CNS lupus diagnosis may 
be determined.
It is quite typical in that lupus patients, including those with renal and central 
nervous system involvement, in general, do quite well with medical compliance. 
Published death rates, transplant rates, and dialysis rates for lupus nephritis are decid-
edly dependent upon the population type that is investigated. A well-educated compli-
ant group of patients has a very low incidence of end stage renal disease while the 
noncompliant group almost certainly ultimately develop end stage renal disease [39].
3.5 Abdominal pain
Another presentation would be abdominal pain, rather than splenomegaly. This 
would account for approximately 27% of lupus symptomatology [29]. A patient 
with severe abdominal pain, who is known to have lupus, after a proper workup for 
exclusion of perforated viscus or ischemic disease, the treatment would be steroids 
for what is mesenteric arteritis or serositis. The prognosis would not change, as they 
are both treated with moderate high dose steroids, oral or IV. Again, this can be a 
presenting feature of lupus. To the detriment of the patient, they are often are seen 
by gastroenterologists, who run a plethora of tests, including CTAs and MRIs of 
various organs, only to ultimately discover a case of hepatosplenomegaly with pain. 
At that point, to the misfortune of the patient, unnecessary surgery is generally per-
formed for the hepatosplenomegaly, and sadly, the patient passes away as a result. If 
the patient had been treated properly, their life could have been saved, as they would 
have been successfully treated with 1 to 2 mg/kg of prednisolone or similar [40].
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3.6 Pancreatitis and Raynaud’s phenomenon
Pancreatitis is an excellent example of a disease, which is not part of the listed 
diagnostic criteria for lupus. Raynaud’s phenomenon also not listed in the diagnostic 
criteria, although approximately 25% of lupus patients suffer from this condition 
[29, 41]. While either of those may be the presenting feature of systemic lupus, nei-
ther are listed as diagnostic criteria which is fine; however, the practitioner should 
perform a thorough workup to determine if a patient who has pancreatitis, as they 
may well have lupus. It should be noted however, that alcoholism, gallstone disease 
and pancreatic divisum, without the atypical sausage pancreas of IgG4-related 
disease, must be ruled out.
With regard to Raynaud’s, the reversible spasm of vessels, usually induced by 
cold or emotional provocation, typically with triple phase color response from 5 to 
60 minutes, is a frequent feature in lupus patients and may well be the initial find-
ing of the disease. The practitioner must look past scleroderma, which has a more 
ominous prognosis than Raynaud’s related to lupus. This is often differentiated with 
a simple in-office nailfold capillaroscopy, which by in large, is a tremendously unde-
rutilized tool [42]. For the well-seasoned rheumatologist, this technique is used 
more often, but it should be used with regularity. In fact, nailfold capillaroscopy 
should be used as a baseline in all potential cases of autoimmune patients.
3.7 Heart and lungs
Attention to the heart and lungs is essential [43]. A patient with recurrent pneu-
monias is more likely to have lupus pneumonitis or an autoinflammatory disease, 
rather than the occurrence of infectious pneumonia every three months. After the 
onset of a second case of pneumonia, a rheumatologist should be consulted, but 
commonly, this does not occur. Regrettably, the patient who is suffering from an 
autoimmune disease has now suffered without a proper diagnosis for an unspecified 
amount of time. At this point, it would be advantageous to the patient to be seen by 
a rheumatologist without further delay.
Other common heart and lung manifestations of lupus include pleurisy and/
or pericardial effusion [44]. Approximately 12% of lupus patients will develop a 
pericardial effusion [29]. Alarmingly, in several medical institutions, the treat-
ment of choice for pericardial effusion is a pericardial window. Unfortunately, as 
in the case of inappropriate splenectomy with abdominal pain in a case of lupus, as 
mentioned earlier, a pericardial window is carries equal efficacy in a lupus patient 
presenting with pericardial effusion. As there is no indication for abdominal 
surgery for a patient with lupus abdominal pain, there is also virtually no indication 
for pericardial window in a lupus pericarditis patient. The incidence of tamponade 
is extraordinarily low. Myxomatosis valvular heart disease or so-called Libman-
Sacks endocarditis, with or without phospholipid antibodies, is another finding that 
should be noted, although this is often woefully overlooked.
3.8 Overlooked autoimmunity
Many lupus patients suffer from autoimmunity that is frequently overlooked 
and therefore; the percentage of sufferers remains uncalculated [45]. The most 
common is likely Hashimoto’s thyroid disease; however, other conditions include 
Graves’ disease, myasthenia gravis, Addison’s disease, primary biliary cirrhosis, 
and autoimmune hepatitis. Each of these has autoimmune associations that should 
not be overlooked. Many of the features potentially seen in Sjogren’s syndrome, or 




granted based on the positive ANA or research criteria, as those patients may well 
have myositis or scleroderma. As mentioned in Part 2 of this chapter, “A Rheum 
with a Different View”, lupus should be considered in every disease.
4. The thought process of a rheumatologist
There are deep gaps between the thought process and treatment plans of a rheu-
matologist versus that of a general internist, family practitioner, ophthalmologist, 
or orthopedic surgeon or any other practitioner involved in a patient’s care.
Rheumatology remains greatly underutilized. This regrettably adds substantial 
delay to the diagnosis and treatment of a patient. It bears mentioning again that 
all organ systems may be involved in lupus. Based on this, the all-purpose criteria 
is preferable to the new SLICC criteria for diagnosis of lupus, as it was far more 
practical [46]. It also bears mentioning again that no practitioner may diagnose 
lupus, or any other disease process, based solely on research criteria. Criteria are 
to be used merely as a guideline. For example, a patient presents to their physi-
cian, stating they are “not feeling well”. Subsequently, blood studies are ordered 
that reveal an ANA with a very high titer and upon further perusal, a very high 
DNA is also discovered, yet the physician fails to recognize that this patient has 
a forme-fruste of lupus. A rheumatologist would have started the patient on 
Plaquenil and educated them with regard to their diagnosis, and the physical 
ramifications to expect in the future.
Two of the most interesting, but also difficult to treat diseases, a physician may 
encounter include pulmonary renal syndrome, presenting with alveolar hemorrhage, 
and glomerular nephritis with ANA, DNA, successfully treated with cyclophospha-
mide [47]. Another rare, but not uncommon complication of lupus, would be TTP 
with or without the ADAMTS13 gene and ocular inflammation and orbital pseudo-
tumor. Consider the case of a patient who presented with true renal failure, visual 
hallucinations and movement disorder. At that point the patient was treated with IV 
Cytoxan and pulse steroids. Therefore, the patient did not have fever; however the 
patient was anemic and had schistocytes with an elevated reticulocyte count. Thus, 
the patient did not fulfill all of the criteria for TTP; therefore, a clinical diagnosis was 
made of the same. The patient responded almost immediately to with all features of 
the disease disappearing with plasma exchange. This is a wonderful case to recall, 
when a hematologist says to a patient, “It cannot be TTP because there is no fever”, 
apparently, this hematologist has lost sight of the fact that the high dose steroids 
likely blunted the fever. They may argue that there are not enough schistocytes [48] 
to fulfill the bacteria, however when schistocytes should not exist, and anemia can-
not be explained, it can only be rationalized that the use of cyclophosphamides and 
high dose steroids lowered the schistocytes [49, 50]. This is a fantastic example of 
why research criteria alone, should never be used for diagnostic purposes.
It is very important to understand the mechanism of action for each disease 
feature, as it will impact a patient’s treatment. For the purpose of example, throm-
bocytopenia will be seen in Sjogren’s syndrome and hypersplenism, while in lupus 
platelet antibodies, both conditions can be present with dry eyes and dry mouth. 
A salivary gland biopsy may not differentiate, as a positive lymphocyte score of 50 
lymphocytes 4mm2, may presumably be seen in either condition. This may lead to 
an overlap diagnosis, or based on the mechanism of thrombocytopenia, it may also 
sway the diagnosis. Pneumonitis, while common in lupus, is seen in other autoim-
mune diseases, including sarcoidosis. All conditions mentioned may have a positive 
rheumatoid factor or positive ANA. Even CCP antibodies can be seen in autoim-
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5. Conclusions
Lupus is a great mimicker. This is due in part to a woeful lack of knowledge by 
most practitioners, as well as the absence of specific treatments. However, based 
on our available knowledge, with earlier institution of proper rheumatologic 
assistance, patients would be diagnosed with greater accuracy and proper treat-
ments begun in a timely manner. Also, with patient compliance, education and 
understanding outcome is better reference. Consulting a rheumatologist promptly, 
would not only benefit the patient, but also profit the medical system by eradicating 
useless tests and treatment options that are often unmerited. Unfortunately, in a 
world of protocol, many are afraid to take an unconventional approach. It is because 
of this; other physicians often fail to consider a rheumatologic consultation [52].
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 





[1] Kuhn A, Bonsmann G, Anders HJ, 
Herzer P, Tenbrock K, Schneider M. The 
Diagnosis and Treatment of Systemic 
Lupus Erythematosus. Dtsch Arztebl 
Int. 2015 Jun 19;112(25):423-32. doi: 
10.3238/arztebl.2015.0423. PMID: 
26179016; PMCID: PMC4558874.
[2] Wallace, Daniel J. (Daniel Jeffrey), 
1949-The lupus book : a guide for patients 
and their families / Daniel J. Wallace. 
– 5th ed.
[3] Tunnicliffe DJ, Palmer SC,  
Henderson L, Masson P, Craig JC, 
Tong A, Singh-Grewal D, Flanc RS, 
Roberts MA, Webster AC, Strippoli GF. 
Immunosuppressive treatment for 
proliferative lupus nephritis. Cochrane 
Database Syst Rev. 2018 Jun 
29;6(6):CD002922. doi: 10.1002/14651858.
CD002922.pub4. PMID: 29957821; 
PMCID: PMC6513226.
[4] Felten R, Scher F, Sagez F, Chasset F, 
Arnaud L. Spotlight on anifrolumab 
and its potential for the treatment of 
moderate-to-severe systemic lupus 
erythematosus: evidence to date. Drug 
Des Devel Ther. 2019 May 8;13:1535-
1543. doi: 10.2147/DDDT.S170969. 
PMID: 31190735; PMCID: PMC6514126.
[5] Baigrie D, Bansal P, Goyal A, 
Crane JS. Leukocytoclastic Vasculitis. 
2020 Aug 11. In: StatPearls [Internet]. 
Treasure Island (FL): StatPearls 
Publishing; 2020 Jan–. PMID: 29489227.
[6] Qiao W, Ding H, Zuo Y, Jiang L,  
Zhou J, Han X, Yu L, Du R, M 
Hedrich C, Deng GM. Lupus IgG 
deposition causes arthritis but inhibits 
bone destruction through competitive 
occupation of FcγRI and reduced 
RANKL signalling. Clin Transl 
Immunology. 2020 Sep 6;9(9):e1174. 
doi: 10.1002/cti2.1174. PMID: 32994999; 
PMCID: PMC7507387.
[7] Komolafe OO. Rapidly progressive 
glomerulonephritis: A wild card 
manifestation of lupus nephritis. Saudi 
J Kidney Dis Transpl. 2018 Mar-
Apr;29(2):443-451. doi: 10.4103/1319-
2442.229293. PMID: 29657218.
[8] Rutgers A, Sanders JS, Stegeman CA,  
Kallenberg CG. Pauci-immune 
necrotizing glomerulonephritis. Rheum 
Dis Clin North Am. 2010 Aug;36(3):559-
572. doi: 10.1016/j.rdc.2010.05.002. 
PMID: 20688250.
[9] DeVrieze BW, Hurley JA. Good-
pasture Syndrome. 2020 Mar 25. In: 
StatPearls [Internet]. Treasure Island 
(FL): StatPearls Publishing; 2020 Jan–. 
PMID: 29083697.
[10] Mustaqeem R, Arif A. Renal 
Tubular Acidosis. 2020 Aug 16. In: 
StatPearls [Internet]. Treasure Island 
(FL): StatPearls Publishing; 2020 Jan–. 
PMID: 30085586.
[11] Muriithi AK, Leung N, Valeri AM, 
et al. Biopsy-proven acute interstitial 
nephritis, 1993-2011: a case series. Am J 
Kidney Dis 2014;64:558-566.
[12] Cortazar FB, Kibbelaar ZA, 
Glezerman IG, et al. Clinical features 
and outcomes of immune checkpoint 
inhibitor-associated AKI: a multi center 
study. J Am Soc Nephrol 2020;31: 
435-446.
[13] Huong DL, Papo T, Beaufils H, 
et al. Renal involvement in systemic 
lupus erythematosus: a study of 180 
patients from a single center. Medicine 
(Baltimore) 1999;78:148-166.
[14] Yu F, Wu L-H, Tan Y, et al. Tubulo-
interstitial lesions of patients with 
lupus nephritis classified by the 2003 
International Society of Nephrology and 
Renal Pathology Society system. Kidney 
Int 2010;77:820-829.
[15] Cortazar FB, Stone JH. IgG4-related 




[16] Raissian Y, Nasr SH, Larsen CP,  
et al. Diagnosis of IgG4-related 
tubulointerstitial nephritis. J Am Soc 
Nephrol 2011;22:1343-1352.
[17] McCabe C, Jones Q, Nikolopoulou A, 
Wathen C, Luqmani R. Pulmonary-
renal syndromes: an update for 
respiratory physicians. Respir Med. 2011 
Oct;105(10):1413-1421. doi: 10.1016/j.
rmed.2011.05.012. PMID: 21684732.
[18] Jennette JC, Nachman PH. ANCA 
Glomerulonephritis and Vasculitis. 
Clin J Am Soc Nephrol. 2017 Oct 
6;12(10):1680-1691. doi: 10.2215/
CJN.02500317. Epub 2017 Aug 25. 
PMID: 28842398; PMCID: PMC5628710.
[19] Saccucci M, Di Carlo G, Bossù M,  
Giovarruscio F, Salucci A, Polimeni A.  
Autoimmune Diseases and Their 
Manifestations on Oral Cavity: Diagnosis 
and Clinical Management. J Immunol 
Res. 2018 May 27;2018:6061825. doi: 
10.1155/2018/6061825. PMID: 29977929; 
PMCID: PMC5994274.
[20] Andrews JS, Trupin L, Schmajuk G, 
Barton J, Margaretten M, Yazdany J, 
Yelin EH, Katz PP. Muscle Strength and 
Changes in Physical Function in Women 
With Systemic Lupus Erythematosus. 
Arthritis Care Res (Hoboken). 2015 
Aug;67(8):1070-7. doi: 10.1002/acr.22560. 
PMID: 25623919; PMCID: PMC4515406.
[21] Lee KC, Ladizinski B, Federman DG. 
Complications associated with use of 
levamisole-contaminated cocaine: an 
emerging public health challenge. Mayo 
Clin Proc. 2012 Jun;87(6):581-6. doi: 
10.1016/j.mayocp.2012.03.010. PMID: 
22677078; PMCID: PMC3498128.
[22] Vasquez-Canizares N, Wahezi D, 
Putterman C. Diagnostic and prognostic 
tests in systemic lupus erythematosus. 
Best Pract Res Clin Rheumatol. 2017 
Jun;31(3):351-363. doi: 10.1016/j.
berh.2017.10.002. Epub 2017 Nov 6. 
PMID: 29224677; PMCID: PMC5776716.
[23] Chanprapaph K, Udompanich S,  
Visessiri Y, Ngamjanyaporn P, 
Suchonwanit P. Nonscarring alopecia 
in systemic lupus erythematosus: A 
cross-sectional study with trichoscopic, 
histopathologic, and immunopathologic 
analyses. J Am Acad Dermatol. 2019 
Dec;81(6):1319-1329. doi: 10.1016/j.
jaad.2019.05.053. Epub 2019 May 28. 
PMID: 31150712.
[24] Jefferson GD, Aakalu VK,  
Braniecki M. Tumid lupus: An 
unexpected diagnosis for the 
otolaryngologist. Am J Otolaryngol. 2017 
Mar-Apr;38(2):257-259. doi: 10.1016/j.
amjoto.2017.01.003. Epub 2017 Jan 17. 
PMID: 28122678; PMCID: PMC5826658.
[25] Klímová A, Seidler Štangová P, 
Svozílková P, Kučera T, Heissigerová J. 
Klinické projevy experimentální autoimunitní 
uveitidy [The Clinical Signs of 
Experimental Autoimmune Uveitis]. 
Cesk Slov Oftalmol. 2016 Feb;72(1):276-
82. Czech. PMID: 27041283.
[26] Tao CY, Shang J, Chen T, Yu D, 
Jiang YM, Liu D, Cheng GY, Xiao J, 
Zhao ZZ. Impact of antimalarial (AM) 
on serum lipids in systemic lupus 
erythematosus (SLE) patients: 
A systematic review and meta-




[27] Chi AC, Neville BW, Krayer JW, 
Gonsalves WC. Oral manifestations of 
systemic disease. Am Fam Physician. 
2010 Dec 1;82(11):1381-1388. PMID: 
21121523.
[28] Carubbi F, Alunno A, Gerli R, 
Giacomelli R. Histopathology of salivary 
glands. Reumatismo. 2018 Oct 
3;70(3):146-154. doi: 10.4081/reuma-
tismo.2018.1053. PMID: 30282440.\
[29] Wallace, Daniel J. (Daniel Jeffrey), 
1949-The lupus book : a guide for 
patients and their families / Daniel J. 




[30] Ceccarelli F, Perricone C, 
Cipriano E, Massaro L, Natalucci F, 
Capalbo G, Leccese I, Bogdanos D, 
Spinelli FR, Alessandri C, Valesini G, 
Conti F. Joint involvement in systemic 
lupus erythematosus: From pathogenesis 
to clinical assessment. Semin Arthritis 
Rheum. 2017 Aug;47(1):53-64. doi: 
10.1016/j.semarthrit.2017.03.022. Epub 
2017 Apr 4. PMID: 28465078.
[31] van Vugt RM, Derksen RH, Kater L, 
Bijlsma JW. Deforming arthropathy 
or lupus and rhupus hands in systemic 
lupus erythematosus. Ann Rheum Dis. 
1998 Sep;57(9):540-4. doi: 10.1136/
ard.57.9.540. PMID: 9849313; PMCID: 
PMC1752746.
[32] Kabadi S, Yeaw J, Bacani AK, 
Tafesse E, Bos K, Karkare S, DeKoven M, 
Vina ER. Healthcare resource utilization 
and costs associated with long-term 
corticosteroid exposure in patients 
with systemic lupus erythematosus. 
Lupus. 2018 Oct;27(11):1799-1809. 
doi: 10.1177/0961203318790675. Epub 
2018 Aug 1. PMID: 30068254; PMCID: 
PMC6264911.
[33] Brierley CK, Pavord S. Autoimmune 
cytopenias and thrombotic thrombo-
cytopenic purpura. Clin Med (Lond). 
2018 Aug;18(4):335-339. doi: 10.7861/
clinmedicine.18-4-335. PMID: 
30072561; PMCID: PMC6334040.
[34] Chimenti MS, Di Stefani A,  
Conigliaro P, Saggini A, Urbani S, 
Giunta A, Esposito M, Bianchi L, Peris K, 
Perricone R. Histopathology of the skin 
in rheumatic diseases. Reumatismo. 
2018 Oct 3;70(3):187-198. doi: 10.4081/
reumatismo.2018.1049. PMID: 30282444.
[35] Jessop S, Whitelaw DA, Grainge MJ, 
Jayasekera P. Drugs for discoid lupus 
erythematosus. Cochrane Database 
Syst Rev. 2017 May 5;5(5):CD002954. 
doi: 10.1002/14651858.CD002954.pub3. 
PMID: 28476075; PMCID: PMC6481466.
[36] Hanly JG, Kozora E, Beyea SD, 
Birnbaum J. Review: Nervous System 
Disease in Systemic Lupus Ery-
thematosus: Current Status and Future 
Directions. Arthritis Rheumatol. 2019 
Jan;71(1):33-42. doi: 10.1002/art.40591. 
Epub 2018 Nov 24. PMID: 29927108.
[37] Kivity S, Agmon-Levin N, 
Zandman-Goddard G, Chapman J, 
Shoenfeld Y. Neuropsychiatric lupus: a 
mosaic of clinical presentations. BMC 
Med. 2015 Mar 4;13:43. doi: 10.1186/
s12916-015-0269-8. PMID: 25858312; 
PMCID: PMC4349748.
[38] Hanly JG, Li Q, Su L, Urowitz MB, 
Gordon C, Bae SC, Romero-Diaz J, 
Sanchez-Guerrero J, Bernatsky S, 
Clarke AE, Wallace DJ, Isenberg DA, 
Rahman A, Merrill JT, Fortin PR, 
Gladman DD, Bruce IN, Petri M, 
Ginzler EM, Dooley MA, Steinsson K, 
Ramsey-Goldman R, Zoma AA, Manzi S, 
Nived O, Jonsen A, Khamashta MA, 
Alarcón GS, van Vollenhoven RF, 
Aranow C, Mackay M, Ruiz-Irastorza G, 
Ramos-Casals M, Lim SS, Inanc M, 
Kalunian KC, Jacobsen S, Peschken CA, 
Kamen DL, Askanase A, Theriault C, 
Farewell V. Psychosis in Systemic Lupus 
Erythematosus: Results From an 
International Inception Cohort Study. 
Arthritis Rheumatol. 2019 Feb;71(2): 
281-289. doi: 10.1002/art.40764. Epub 
2019 Jan 18. PMID: 30375754; PMCID: 
PMC6353684.
[39] Tesar V, Hruskova Z. Lupus 
Nephritis: A Different Disease in 
European Patients? Kidney Dis 
(Basel). 2015 Sep;1(2):110-8. doi: 
10.1159/000438844. Epub 2015 Aug 28. 
PMID: 27536671; PMCID: PMC4934820.
[40] Adler BL, Timlin H, Birnbaum J. 
Lupus intestinal pseudo-obstruction 
and hydronephrosis: Case report. 




[41] Hesselstrand R, Iagnocco A, 
Kayser C, Melsens K, Müller-Ladner U, 
Lupus
14
Paolino S, Pizzorni C, Radic M, Riccieri V, 
Snow M, Stevens W, Sulli A, van Laar JM, 
Vonk MC, Vanhaecke A, Cutolo M; 
EULAR Study Group on Microcirculation 
in Rheumatic Diseases and the 
Scleroderma Clinical Trials Consortium 
Group on Capillaroscopy. Standardisation 
of nailfold capillaroscopy for the 
assessment of patients with Raynaud's 
phenomenon and systemic sclerosis. 
Autoimmun Rev. 2020 Mar;19(3):102458. 
doi: 10.1016/j.autrev.2020.102458. Epub 
2020 Jan 10. PMID: 31927087.
[42] Smith V, Herrick AL,  
Ingegnoli F, Damjanov N, De 
Angelis R, Denton CP, Distler O, 
Espejo K, Foeldvari I, Frech T, Garro B, 
Gutierrez M, Gyger G, Hachulla E, 
Hesselstrand R, Iagnocco A, Kayser C, 
Melsens K, Müller-Ladner U, Paolino S, 
Pizzorni C, Radic M, Riccieri V, Snow M, 
Stevens W, Sulli A, van Laar JM, Vonk MC, 
Vanhaecke A, Cutolo M; EULAR 
Study Group on Microcirculation in 
Rheumatic Diseases and the Scleroderma 
Clinical Trials Consortium Group 
on Capillaroscopy. Standardisation 
of nailfold capillaroscopy for the 
assessment of patients with Raynaud's 
phenomenon and systemic sclerosis. 
Autoimmun Rev. 2020 Mar;19(3):102458. 
doi: 10.1016/j.autrev.2020.102458. Epub 
2020 Jan 10. PMID: 31927087.
[43] Signorini V, Elefante E, Zucchi D, 
Trentin F, Bortoluzzi A, Tani C. One 
year in review 2020: systemic lupus 
erythematosus. Clin Exp Rheumatol. 
2020 Jul-Aug;38(4):592-601. Epub 2020 
Jul 10. PMID: 32662410.
[44] Bezwada P, Quadri A, Shaikh A,  
Ayala-Rodriguez C, Green S.  
Myopericarditis and Pericardial 
Effusion as the Initial Presentation of 
Systemic Lupus Erythematosus. Case 
Rep Med. 2017;2017:6912020. doi: 
10.1155/2017/6912020. Epub 2017 Feb 5. 
PMID: 28261271; PMCID: PMC5316435.
[45] Basta F, Fasola F, Triantafyllias K,  
Schwarting A. Systemic Lupus 
Erythematosus (SLE) Therapy: The Old 
and the New. Rheumatol Ther. 2020 
Sep;7(3):433-446. doi: 10.1007/s40744-
020-00212-9. Epub 2020 Jun 2. PMID: 
32488652; PMCID: PMC7410873.
[46] Tiao J, Feng R, Carr K, Okawa J, 
Werth VP. Using the American College 
of Rheumatology (ACR) and Systemic 
Lupus International Collaborating 
Clinics (SLICC) criteria to determine 
the diagnosis of systemic lupus 
erythematosus (SLE) in patients with 
subacute cutaneous lupus erythematosus 
(SCLE). J Am Acad Dermatol. 2016 
May;74(5):862-9. doi: 10.1016/j.
jaad.2015.12.029. Epub 2016 Feb 18. 
PMID: 26897388; PMCID: PMC4879000.
[47] Nasser M, Cottin V. The Respiratory 
System in Autoimmune Vascular 
Diseases. Respiration. 2018;96(1):12-28. 
doi: 10.1159/000486899. Epub 2018 Jul 
4. PMID: 29975964.
[48] Nasser M, Cottin V. The Respiratory 
System in Autoimmune Vascular 
Diseases. Respiration. 2018;96(1):12-28. 
doi: 10.1159/000486899. Epub 2018 Jul 
4. PMID: 29975964.
[49] Schapkaitz E, Mezgebe MH. The 
Clinical Significance of Schistocytes: 
A Prospective Evaluation of the 
International Council for Standardization 
in Hematology Schistocyte Guidelines. 
Turk J Haematol. 2017 Mar 1;34(1):59-
63. doi: 10.4274/tjh.2016.0359. Epub 
2016 Oct 31. PMID: 27795225; PMCID: 
PMC5451690.
[50] Chiasakul T, Cuker A. Clinical 
and laboratory diagnosis of TTP: an 
integrated approach. Hematology 
Am Soc Hematol Educ Program. 2018 
Nov 30;2018(1):530-538. doi: 10.1182/
asheducation-2018.1.530. PMID: 
30504354; PMCID: PMC6246034.
[51] Soloway A, Late-onset Systemic 
Lupus Erythematosus Presenting 




Nephritis, 2019 ACP Poster Contest 
Winner NYS
[52] Hoover PJ, Costenbader KH. 
Insights into the epidemiology and 
management of lupus nephritis from 
the US rheumatologist's perspective. 
Kidney Int. 2016 Sep;90(3):487-92. 
doi: 10.1016/j.kint.2016.03.042. Epub 
2016 Jun 22. PMID: 27344205; PMCID: 
PMC5679458.
